Skip to main content

Table 3 Correlations between bone markers, inflammatory variables and IGFSD at different time-points and changes in bone mineral density during 24 months for the two treatment groups

From: Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study

 

Prednisolone group

No prednisolone group

 

Δ BMD L2 toL4, 0 to 24 months

Δ BMD neck, 0 to 24 months

Δ BMD L2 to L4, 0 to 24 months

Δ BMD neck, 0 to 24 months

Age

ns

Ns

ns

ns

BMI, baseline

ns

r = 0.26, p = 0.031

ns

r = 0.39, p < 0.001

P1NP, baseline

ns

Ns

r = -0.36, p = 0.002

ns

P1NP, 12 months

r = -0.24, p = 0.057

r = -0.30, p = 0.018

r = -0.37, p = 0.002

ns

ΔP1NP, 0 to 12 months

ns

ns

ns

ns

CTX-1, baseline

ns

ns

ns

ns

CTX-1, 12 months

ns

ns

r = -0.36, p = 0.002

ns

ΔCTX-1, 0 to12 months

ns

r = -0.26, p = 0.045

ns

ns

1CTP, baseline

ns

ns

ns

r = -0.27, p = 0.020

1CTP, 12 months

ns

r = -0.24, p = 0.059

r = -0.28, p = 0.017

r = -0.22, p = 0.072

Δ1CTP, 0 to 12 months

r = -0.29, p = 0.026

r = -0.33, p = 0.010

ns

Ns

ESR, baseline

ns

ns

ns

r = -0.24, p = 0.031

ESR, 12 months

ns

ns

r = -0.33, p = 0.004

r = -0.22, p = 0.053

CRP, baseline

ns

ns

ns

r = -0.28, p = 0.012

CRP, 12 months

ns

ns

r = -0.28, p = 0.015

r = -0.30, p = 0.008

IL-6, baseline

ns

ns

ns

ns

IL-6, 12 months

ns

r = -0.25, p = 0.037

ns

ns

IGFSD, baseline

r = 0.36, p = 0.003

ns

ns

ns

IGFSD, 12 months

ns

ns

ns

ns

ΔIGFSD, 0 to 12 months

r = -0.31, p = 0.017

ns

ns

r = -0.25, p = 0.038

  1. BMI = body mass index; CRP = C-reactive protein; 1CTP = C-terminal propeptide of type I collagen; CTX = C-terminal telopeptides crosslaps; ESR = erythrocyte sedimentation rate; IGFSD = insulin-like growth factor-1, standard deviation scores; IL-6 = interleukin-6; ns = not significant; P1NP = Procollagen type I N-terminal propeptide. Bold p values are statistically significant.